Published in Medical Letter on the CDC and FDA, November 8th, 2009
Apremilast is an oral pluripotent immunomodulator that inhibits the activity of PDE4 and modulates the production of multiple pro-inflammatory mediators, including TNF-a, IL-2 IL-10, IL-17, and IL-23.
CC-10004-PSA-001 sought to determine the efficacy and safety of apremilast in 204 patients at two different dosing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA